| Current Price | $139.73 | Mkt Cap | $6.4B |
|---|---|---|---|
| Open | $149.37 | P/E Ratio | 6.22 |
| Prev. Close | $139.73 | Div. (Yield) | $0.00 (0.0%) |
| Daily Range | $139.10 - $150.79 | Volume | 833,548 |
| 52-Wk Range | $103.31 - $306.72 | Avg. Daily Vol. | 890,981 |
The Company is engaged in the development, manufacturing and marketing of rapid diagnostic solutions at the professional point-of-care in infectious diseases and reproductive health.
| Current Price | $139.73 | Mkt Cap | $6.4B |
|---|---|---|---|
| Open | $149.37 | P/E Ratio | 6.22 |
| Prev. Close | $139.73 | Div. (Yield) | $0.00 (0.0%) |
| Daily Range | $139.10 - $150.79 | Volume | 833,548 |
| 52-Wk Range | $103.31 - $306.72 | Avg. Daily Vol. | 890,981 |
The best Bull and Bear pitches based on recency and number of recommendations.
This is one of my STARZ.Here is the thought process on this STAR: a) Divided rate over Zerob) 3 Year Beta between -5 & +3c) 15% + Insider ownershipd) No greater than -50% Growth rate for the last 3 years (tough last couple of years so good that… More
Price has become too high,,,long way to fall. Check out 10-year chart...
Read the most recent pitches from players about QDEL.
Recs
katalambda
(< 20)
Submitted: 7/16/2021 3:34:53 PM :
Start Price:
$124.78
NASDAQ:QDEL Score:
+9.77
Right now QDEL is undervaluated, Not only Quidel has a Piotroski score of 9 it also has an outstanding ROIC and ROE. QDEL sells growth its amazing and the debt is not a problem. The stock is a no brainer.
Recs
Kentuckyfarmer
(50.61)
Submitted: 6/19/2021 6:37:01 PM :
Start Price:
$112.72
NASDAQ:QDEL Score:
+18.15
Growing revenues and the price is down 50% from its highs due to the market thinking covid testing is done. But covid testing with the new variants appears to be here a while.
Recs
neibuhr
(62.36)
Submitted: 6/2/2021 2:06:41 PM :
Start Price:
$109.03
NASDAQ:QDEL Score:
+23.20
At its current price, Quidel offers both superior long-term growth potential and relative value. Quidel's Covid testing-related revenues are diminishing, but, looking forward, its seasonal flu testing-related revenues are likely to partially offset those lost revenues. Also, Quidel has several other existing and potential diagnostic products/services in its pipeline with significant growth potential, as projected by Quidel's management.
On a risk/reward basis, Quidel looks attractive here.
Find the members with the highest scoring picks in QDEL.
robertsylvia (< 20) Score: +1,208.31
The Score Leader is the player with the highest score across all their picks in QDEL.
|
Top Pick |
Member Name |
Member Rating |
Start Date |
Call |
Time Frame |
Start Price |
Stock Gain |
Index Gain |
Score | Commentary |
|---|---|---|---|---|---|---|---|---|---|---|
| WildCAPS | 80.11 | 3/17/2009 |
|
3M | $7.77 | +1,698.33% | +490.02% | +1,208.31 | 0 Comment | |
| robertsylvia | < 20 | 3/17/2009 |
|
NS | $7.77 | +1,698.33% | +490.02% | +1,208.31 | 0 Comment | |
| SSPX3 | < 20 | 4/24/2009 |
|
NS | $8.50 | +1,543.88% | +418.01% | +1,125.87 | 0 Comment | |
| saaf569 | < 20 | 3/23/2009 |
|
3Y | $8.59 | +1,526.66% | +465.95% | +1,060.71 | 0 Comment | |
| jygalye | < 20 |
|
|
1Y | $10.36 | +1,248.75% | +226.02% | +1,022.73 | 0 Comment | |
| danonwilfon | 49.98 | 3/1/2007 |
|
3M | $10.65 | +1,212.02% | +235.94% | +976.07 | 0 Comment | |
| MrProbabilistic | 74.87 | 3/9/2007 |
|
NS | $10.84 | +1,189.02% | +231.25% | +957.78 | 1 Comment | |
| acf8vj | < 20 | 3/12/2007 |
|
3M | $11.04 | +1,165.67% | +232.92% | +932.75 | 0 Comment | |
| meyring | < 20 | 8/28/2006 |
|
1Y | $11.16 | +1,152.06% | +262.58% | +889.48 | 0 Comment | |
| Klavierspieler | 87.26 | 9/30/2010 |
|
5Y | $11.05 | +1,164.52% | +283.33% | +881.20 | 0 Comment |
See what the Wall Street professionals think, according to their public statements and filings.
